Discover trends, market shifts, and competitive outlooks for the pegfilgrastim biosimilars industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What is the Projected CAGR for the Pegfilgrastim Biosimilars Market Size from 2025 to 2034?

The market size of pegfilgrastim biosimilars has quickly expanded in the past few years. This growth is projected to rise from $1.56 billion in 2024 to approximately $1.8 billion in 2025, with a compound annual growth rate (CAGR) of 15.3%. Factors contributing to this growth during the historical period include a higher prevalence rate of cancer, governmental initiatives, an increase in healthcare spending, a rise in biopharmaceutical R&D expenses, the affordability of biosimilars, and a significant penetration rate of biosimilar drugs.

The market for pegfilgrastim biosimilars is projected to exhibit swift expansion in the coming years, surging to $3.44 billion by 2029 with a compound annual growth rate (CAGR) of 17.5%. Factors contributing to the expected growth during this forecast period include the rising incidence of cancer, an aging demographic, an increase in approvals, and overarching targets and incentives. Expected trends throughout the same period are to capitalize on less stringent regulations to innovate new and better biosimilars, significant investments towards research and development for creating more efficient and groundbreaking biologics, pursuing strategic collaborations with significant players for broadening research and development pursuits in new drug development, intensifying focus on growth strategies related to mergers and acquisitions for widening customer reach and geographical market presence, and amplifying the focus on the manufacture of biosimilars for treating neutropenia with the goal to enhance revenues and product offerings.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of thePegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market is likely to be stimulated by government efforts focused on biosimilar development. Globally, governments are turning their focus towards biosimilars as they are economical. The Biosimilar Action Plan, launched by the US Food and Drug Administration (FDA), aims to expand treatment options. Likewise, the Australian government’s advocacy for the Biosimilar Awareness Initiative has been fortified by backing the Generic and Biosimilar Medicines Association with a $5 million grant, promoting increased general awareness and activities related to appropriate dispensing, prescribing and usage of biosimilar medicines. Therefore, these governmental movements towards the development of biosimilars positively contribute to the expansion and awareness, consequently bolstering the growth of the pegfilgrastim biosimilars market.

Which Segments in the Pegfilgrastim Biosimilars Offer the Most Growth?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia, Other Supportive Therapies in Oncology

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=4015&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of thePegfilgrastim Biosimilars Market?# Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2024. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Current Market Growth and Trends in the Pegfilgrastim Biosimilars Industry?

In a drive for product innovation, firms within the pegfilgrastim biosimilar market are expanding their strategic collaborations. To maintain their position in the competitive market, these companies are focusing on the development of innovative products and an exchange of skills and expertise with peers. The pattern of fostering collaboration between companies and academic or research institutions through partnerships or out-licensing tactics in this market has seen a rise in recent years. To illustrate this, in May 2023, a partnership was formed between Amneal Pharmaceuticals, a generics and specialty pharmaceutical firm based in the US, and Kashiv Biosciences, an integrated biosciences company also based in the US. The collaboration aimed to develop and launch Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. Fylnetra, a clear, preservative-free solution packed in a 6 mg/0.6 mL single-dose prefilled syringe, is intended to curtail the risk of infections, distinctly febrile neutropenia, in non-myeloid cancer patients undergoing specific myelosuppressive anti-cancer treatments.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

What Are the Key Elements That Define the Pegfilgrastim Biosimilars Market?

Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4015

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model